{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:41:10Z","timestamp":1793662870705,"version":"4.5.1"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41584-024-01179-5","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T04:11:04Z","timestamp":1730952664000},"page":"770-782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-7725","authenticated-orcid":false,"given":"Thomas","family":"D\u00f6rner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9287-1676","authenticated-orcid":false,"given":"Peter E.","family":"Lipsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"1179_CR1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1136\/ard-2023-224225","volume":"82","author":"M Akiyama","year":"2023","unstructured":"Akiyama, M., Alshehri, W., Yoshimoto, K. & Kaneko, Y. T follicular helper cells and T peripheral helper cells in rheumatic and musculoskeletal diseases. Ann. Rheum. Dis. 82, 1371\u20131381 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1179_CR2","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.4049\/jimmunol.1701728","volume":"200","author":"C Giesecke","year":"2018","unstructured":"Giesecke, C. et al. Simultaneous presence of non- and highly mutated keyhole limpet hemocyanin (KLH)-specific plasmablasts early after primary KLH immunization suggests cross-reactive memory B cell activation. J. Immunol. 200, 3981\u20133992 (2018).","journal-title":"J. Immunol."},{"key":"1179_CR3","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.4049\/jimmunol.1302783","volume":"192","author":"C Giesecke","year":"2014","unstructured":"Giesecke, C. et al. Tissue distribution and dependence of responsiveness of human antigen-specific memory B cells. J. Immunol. 192, 3091\u20133100 (2014).","journal-title":"J. Immunol."},{"key":"1179_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/ar3433","volume":"13","author":"T Dorner","year":"2011","unstructured":"Dorner, T., Giesecke, C. & Lipsky, P. E. Mechanisms of B cell autoimmunity in SLE. Arthritis Res. Ther. 13, 243 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"1179_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/nrneph.2016.20","volume":"12","author":"F Hiepe","year":"2016","unstructured":"Hiepe, F. & Radbruch, A. Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat. Rev. Nephrol. 12, 232\u2013240 (2016).","journal-title":"Nat. Rev. Nephrol."},{"key":"1179_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.immuni.2019.12.005","volume":"52","author":"SA Jenks","year":"2020","unstructured":"Jenks, S. A. et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 52, 203 (2020).","journal-title":"Immunity"},{"key":"1179_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1146\/annurev-immunol-092419-031130","volume":"38","author":"MP Cancro","year":"2020","unstructured":"Cancro, M. P. Age-associated B cells. Annu. Rev. Immunol. 38, 315\u2013340 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"1179_CR8","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41586-024-07627-2","volume":"631","author":"C Law","year":"2024","unstructured":"Law, C. et al. Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus. Nature 631, 857\u2013866 (2024).","journal-title":"Nature"},{"key":"1179_CR9","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMra1100359","volume":"365","author":"GC Tsokos","year":"2011","unstructured":"Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110\u20132121 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/imr.12741","volume":"288","author":"SA Jenks","year":"2019","unstructured":"Jenks, S. A., Cashman, K. S., Woodruff, M. C., Lee, F. E. & Sanz, I. Extrafollicular responses in humans and SLE. Immunol. Rev. 288, 136\u2013148 (2019).","journal-title":"Immunol. Rev."},{"key":"1179_CR11","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar3910","volume":"15","author":"V Reddy","year":"2013","unstructured":"Reddy, V., Jayne, D., Close, D. & Isenberg, D. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res. Ther. 15, S2 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"1179_CR12","doi-asserted-by":"publisher","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","volume":"165","author":"M Odendahl","year":"2000","unstructured":"Odendahl, M. et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165, 5970\u20135979 (2000).","journal-title":"J. Immunol."},{"key":"1179_CR13","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/art.10949","volume":"48","author":"AM Jacobi","year":"2003","unstructured":"Jacobi, A. M. et al. Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 48, 1332\u20131342 (2003).","journal-title":"Arthritis Rheum."},{"key":"1179_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","volume":"49","author":"SA Jenks","year":"2018","unstructured":"Jenks, S. A. et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity 49, 725\u2013739.e726 (2018).","journal-title":"Immunity"},{"key":"1179_CR15","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.4049\/jimmunol.1501209","volume":"195","author":"K Rubtsova","year":"2015","unstructured":"Rubtsova, K., Rubtsov, A. V., Cancro, M. P. & Marrack, P. Age-associated B cells: a T-bet-dependent effector with roles in protective and pathogenic immunity. J. Immunol. 195, 1933\u20131937 (2015).","journal-title":"J. Immunol."},{"key":"1179_CR16","doi-asserted-by":"publisher","unstructured":"Rincon-Arevalo, H. et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.abj1031 (2021).","DOI":"10.1126\/sciimmunol.abj1031"},{"key":"1179_CR17","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/art.42157","volume":"74","author":"F Szelinski","year":"2022","unstructured":"Szelinski, F. et al. Plasmablast-like phenotype among antigen-experienced CXCR5-CD19low B cells in systemic lupus erythematosus. Arthritis Rheumatol. 74, 1556\u20131568 (2022).","journal-title":"Arthritis Rheumatol."},{"key":"1179_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-immunol-101921-042422","volume":"41","author":"S Caielli","year":"2023","unstructured":"Caielli, S., Wan, Z. & Pascual, V. Systemic lupus erythematosus pathogenesis: interferon and beyond. Annu. Rev. Immunol. 41, 533\u2013560 (2023).","journal-title":"Annu. Rev. Immunol."},{"key":"1179_CR19","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nrrheum.2016.158","volume":"12","author":"T Dorner","year":"2016","unstructured":"Dorner, T. & Lipsky, P. E. Beyond pan-B-cell-directed therapy \u2013 new avenues and insights into the pathogenesis of SLE. Nat. Rev. Rheumatol. 12, 645\u2013657 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1179_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48570-0","volume":"15","author":"M Ferreira-Gomes","year":"2024","unstructured":"Ferreira-Gomes, M. et al. Recruitment of plasma cells from IL-21-dependent and IL-21-independent immune reactions to the bone marrow. Nat. Commun. 15, 4182 (2024).","journal-title":"Nat. Commun."},{"key":"1179_CR21","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1002\/art.20519","volume":"50","author":"A Hutloff","year":"2004","unstructured":"Hutloff, A. et al. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum. 50, 3211\u20133220 (2004).","journal-title":"Arthritis Rheum."},{"key":"1179_CR22","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3389\/fimmu.2019.02136","volume":"10","author":"SY Weissenberg","year":"2019","unstructured":"Weissenberg, S. Y. et al. Identification and characterization of post-activated B cells in systemic autoimmune diseases. Front. Immunol. 10, 2136 (2019).","journal-title":"Front. Immunol."},{"key":"1179_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/BOR.0000000000000576","volume":"31","author":"E Schrezenmeier","year":"2019","unstructured":"Schrezenmeier, E. et al. Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations. Curr. Opin. Rheumatol. 31, 175\u2013184 (2019).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1179_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41584-024-01159-9","volume":"20","author":"RH Scofield","year":"2024","unstructured":"Scofield, R. H. & Lewis, V. M. Is X chromosome inactivation a cause or effect of SLE? Nat. Rev. Rheumatol. 20, 599\u2013600 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1179_CR25","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","volume":"382","author":"M Wahren-Herlenius","year":"2013","unstructured":"Wahren-Herlenius, M. & Dorner, T. Immunopathogenic mechanisms of systemic autoimmune disease. Lancet 382, 819\u2013831 (2013).","journal-title":"Lancet"},{"key":"1179_CR26","doi-asserted-by":"publisher","unstructured":"Gemmati, D. et al. COVID-19 and individual genetic susceptibility\/receptivity: role of ACE1\/ACE2 genes, immunity, inflammation and coagulation. Might the double X-chromosome in females be protective against SARS-CoV-2 compared to the single X-chromosome in males? Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms21103474 (2020).","DOI":"10.3390\/ijms21103474"},{"key":"1179_CR27","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41577-020-0348-8","volume":"20","author":"EP Scully","year":"2020","unstructured":"Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C. & Klein, S. L. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat. Rev. Immunol. 20, 442\u2013447 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"1179_CR28","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.4049\/jimmunol.1200745","volume":"189","author":"I Moisini","year":"2012","unstructured":"Moisini, I. et al. The Yaa locus and IFN-\u03b1 fine-tune germinal center B cell selection in murine systemic lupus erythematosus. J. Immunol. 189, 4305\u20134312 (2012).","journal-title":"J. Immunol."},{"key":"1179_CR29","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1002\/art.23701","volume":"58","author":"RH Scofield","year":"2008","unstructured":"Scofield, R. H. et al. Klinefelter\u2019s syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum. 58, 2511\u20132517 (2008).","journal-title":"Arthritis Rheum."},{"key":"1179_CR30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.cell.2023.12.037","volume":"187","author":"DR Dou","year":"2024","unstructured":"Dou, D. R. et al. Xist ribonucleoproteins promote female sex-biased autoimmunity. Cell 187, 733\u2013749.e16 (2024).","journal-title":"Cell"},{"key":"1179_CR31","doi-asserted-by":"publisher","unstructured":"Souyris, M. et al. TLR7 escapes X chromosome inactivation in immune cells. Sci. Immunol. https:\/\/doi.org\/10.1126\/sciimmunol.aap8855 (2018).","DOI":"10.1126\/sciimmunol.aap8855"},{"key":"1179_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","volume":"605","author":"GJ Brown","year":"2022","unstructured":"Brown, G. J. et al. TLR7 gain-of-function genetic variation causes human lupus. Nature 605, 349\u2013356 (2022).","journal-title":"Nature"},{"key":"1179_CR33","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adn6537","volume":"10","author":"C Huret","year":"2024","unstructured":"Huret, C. et al. Altered X-chromosome inactivation predisposes to autoimmunity. Sci. Adv. 10, eadn6537 (2024).","journal-title":"Sci. Adv."},{"key":"1179_CR34","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/sj.ejhg.5201827","volume":"15","author":"RR Graham","year":"2007","unstructured":"Graham, R. R. et al. Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE. Eur. J. Hum. Genet. 15, 823\u2013830 (2007).","journal-title":"Eur. J. Hum. Genet."},{"key":"1179_CR35","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1056\/NEJMoa021933","volume":"349","author":"MR Arbuckle","year":"2003","unstructured":"Arbuckle, M. R. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349, 1526\u20131533 (2003).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR36","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1136\/annrheumdis-2015-208140","volume":"75","author":"ME Munroe","year":"2016","unstructured":"Munroe, M. E. et al. Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann. Rheum. Dis. 75, 2014\u20132021 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1179_CR37","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1136\/annrheumdis-2021-221662","volume":"81","author":"EL Hubbard","year":"2022","unstructured":"Hubbard, E. L., Pisetsky, D. S. & Lipsky, P. E. Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE. Ann. Rheum. Dis. 81, 632\u2013643 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1179_CR38","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/ni.3175","volume":"16","author":"CM Tipton","year":"2015","unstructured":"Tipton, C. M. et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat. Immunol. 16, 755\u2013765 (2015).","journal-title":"Nat. Immunol."},{"key":"1179_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F Muller","year":"2024","unstructured":"Muller, F. et al. CD19 CAR T-cell therapy in autoimmune disease \u2013 a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR40","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1056\/NEJMc2407150","volume":"391","author":"T Alexander","year":"2024","unstructured":"Alexander, T., Kronke, J., Cheng, Q., Keller, U. & Kronke, G. Teclistamab-induced remission in refractory systemic lupus erythematosus. N. Engl. J. Med. 391, 864\u2013866 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR41","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","volume":"113","author":"T Alexander","year":"2009","unstructured":"Alexander, T. et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113, 214\u2013223 (2009).","journal-title":"Blood"},{"key":"1179_CR42","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.4049\/jimmunol.0803391","volume":"182","author":"J Lee","year":"2009","unstructured":"Lee, J., Kuchen, S., Fischer, R., Chang, S. & Lipsky, P. E. Identification and characterization of a human CD5+ pre-naive B cell population. J. Immunol. 182, 4116\u20134126 (2009).","journal-title":"J. Immunol."},{"key":"1179_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1093208","volume":"14","author":"L Wen","year":"2023","unstructured":"Wen, L. et al. Toll-like receptors 7 and 9 regulate the proliferation and differentiation of B cells in systemic lupus erythematosus. Front. Immunol. 14, 1093208 (2023).","journal-title":"Front. Immunol."},{"key":"1179_CR44","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nri3806","volume":"15","author":"J Crouse","year":"2015","unstructured":"Crouse, J., Kalinke, U. & Oxenius, A. Regulation of antiviral T cell responses by type I interferons. Nat. Rev. Immunol. 15, 231\u2013242 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"1179_CR45","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1093\/rheumatology\/keaa187","volume":"59","author":"A Aue","year":"2020","unstructured":"Aue, A. et al. Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility. Rheumatology 59, 3435\u20133442 (2020).","journal-title":"Rheumatology"},{"key":"1179_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03750-7","volume":"9","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE. Nat. Commun. 9, 1758 (2018).","journal-title":"Nat. Commun."},{"key":"1179_CR47","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.4049\/jimmunol.178.5.2872","volume":"178","author":"R Ettinger","year":"2007","unstructured":"Ettinger, R. et al. IL-21 and BAFF\/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J. Immunol. 178, 2872\u20132882 (2007).","journal-title":"J. Immunol."},{"key":"1179_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jim.2010.06.009","volume":"363","author":"T Dorner","year":"2011","unstructured":"Dorner, T., Jacobi, A. M., Lee, J. & Lipsky, P. E. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J. Immunol. Methods 363, 187\u2013197 (2011).","journal-title":"J. Immunol. Methods"},{"key":"1179_CR49","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1002\/eji.202170126","volume":"51","author":"A Cossarizza","year":"2021","unstructured":"Cossarizza, A. et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). Eur. J. Immunol. 51, 2708\u20133145 (2021).","journal-title":"Eur. J. Immunol."},{"key":"1179_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107487","volume":"26","author":"JJ Wilson","year":"2023","unstructured":"Wilson, J. J. et al. Glucose oxidation-dependent survival of activated B cells provides a putative novel therapeutic target for lupus treatment. iScience 26, 107487 (2023).","journal-title":"iScience"},{"key":"1179_CR51","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1182\/blood-2012-04-424648","volume":"120","author":"C Daridon","year":"2012","unstructured":"Daridon, C. et al. Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia. Blood 120, 5021\u20135031 (2012).","journal-title":"Blood"},{"key":"1179_CR52","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1084\/jem.20150537","volume":"213","author":"A Getahun","year":"2016","unstructured":"Getahun, A., Beavers, N. A., Larson, S. R., Shlomchik, M. J. & Cambier, J. C. Continuous inhibitory signaling by both SHP-1 and SHIP-1 pathways is required to maintain unresponsiveness of anergic B cells. J. Exp. Med. 213, 751\u2013769 (2016).","journal-title":"J. Exp. Med."},{"key":"1179_CR53","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.4049\/jimmunol.1203525","volume":"190","author":"KM Nickerson","year":"2013","unstructured":"Nickerson, K. M., Cullen, J. L., Kashgarian, M. & Shlomchik, M. J. Exacerbated autoimmunity in the absence of TLR9 in MRL.Faslpr mice depends on Ifnar1. J. Immunol. 190, 3889\u20133894 (2013).","journal-title":"J. Immunol."},{"key":"1179_CR54","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1016\/j.ajpath.2020.07.015","volume":"190","author":"SE Dorraji","year":"2020","unstructured":"Dorraji, S. E. et al. Kidney tertiary lymphoid structures in lupus nephritis develop into large interconnected networks and resemble lymph nodes in gene signature. Am. J. Pathol. 190, 2203\u20132225 (2020).","journal-title":"Am. J. Pathol."},{"key":"1179_CR55","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000292","volume":"2","author":"T Rose","year":"2016","unstructured":"Rose, T. et al. SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sj\u00f6gren\u2019s syndrome. RMD Open. 2, e000292 (2016).","journal-title":"RMD Open."},{"key":"1179_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901437","volume":"13","author":"T Iwasaki","year":"2022","unstructured":"Iwasaki, T. et al. Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis. Front. Immunol. 13, 901437 (2022).","journal-title":"Front. Immunol."},{"key":"1179_CR57","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/BOR.0b013e32835c7e32","volume":"25","author":"L Ronnblom","year":"2013","unstructured":"Ronnblom, L. & Eloranta, M. L. The interferon signature in autoimmune diseases. Curr. Opin. Rheumatol. 25, 248\u2013253 (2013).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1179_CR58","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000082101","volume":"8","author":"G Jego","year":"2005","unstructured":"Jego, G., Pascual, V., Palucka, A. K. & Banchereau, J. Dendritic cells control B cell growth and differentiation. Curr. Dir. Autoimmun. 8, 124\u2013139 (2005).","journal-title":"Curr. Dir. Autoimmun."},{"key":"1179_CR59","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf, L. et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N. Engl. J. Med. 383, 1149\u20131155 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR60","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/acr2.11511","volume":"5","author":"DJ Wallace","year":"2023","unstructured":"Wallace, D. J. et al. Efficacy and safety of the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled dose-ranging trial. ACR Open. Rheumatol. 5, 38\u201348 (2023).","journal-title":"ACR Open. Rheumatol."},{"key":"1179_CR61","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/art.41811","volume":"73","author":"D Isenberg","year":"2021","unstructured":"Isenberg, D. et al. Efficacy, safety, and pharmacodynamic effects of the Bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 73, 1835\u20131846 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1179_CR62","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.39856","volume":"69","author":"ME Clowse","year":"2017","unstructured":"Clowse, M. E. et al. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 69, 362\u2013375 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1179_CR63","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/art.42652","volume":"75","author":"JT Merrill","year":"2023","unstructured":"Merrill, J. T. et al. Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial. Arthritis Rheumatol. 75, 2185\u20132194 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1179_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2016-000163","volume":"3","author":"M Ryden-Aulin","year":"2016","unstructured":"Ryden-Aulin, M. et al. Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Sci. Med. 3, e000163 (2016).","journal-title":"Lupus Sci. Med."},{"key":"1179_CR65","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/RHU.0b013e31824e8d9b","volume":"18","author":"MP Keith","year":"2012","unstructured":"Keith, M. P., Pitchford, C. & Bernstein, W. B. Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus. J. Clin. Rheumatol. 18, 134\u2013137 (2012).","journal-title":"J. Clin. Rheumatol."},{"key":"1179_CR66","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41409-018-0173-x","volume":"53","author":"RK Burt","year":"2018","unstructured":"Burt, R. K. et al. Five year follow-up after autologous peripheral blood hematopoietic stem cell transplantation for refractory, chronic, corticosteroid-dependent systemic lupus erythematosus: effect of conditioning regimen on outcome. Bone Marrow Transplant. 53, 692\u2013700 (2018).","journal-title":"Bone Marrow Transplant."},{"key":"1179_CR67","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1002\/art.34400","volume":"64","author":"W Stohl","year":"2012","unstructured":"Stohl, W. et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64, 2328\u20132337 (2012).","journal-title":"Arthritis Rheum."},{"key":"1179_CR68","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.ebiom.2018.12.035","volume":"40","author":"D Ramskold","year":"2019","unstructured":"Ramskold, D. et al. B cell alterations during BAFF inhibition with belimumab in SLE. EBioMedicine 40, 517\u2013527 (2019).","journal-title":"EBioMedicine"},{"key":"1179_CR69","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.27189","volume":"62","author":"AM Jacobi","year":"2010","unstructured":"Jacobi, A. M. et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 62, 201\u2013210 (2010).","journal-title":"Arthritis Rheum."},{"key":"1179_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1080730","volume":"14","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients. Front. Pharmacol. 14, 1080730 (2023).","journal-title":"Front. Pharmacol."},{"key":"1179_CR71","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918\u20133930 (2011).","journal-title":"Arthritis Rheum."},{"key":"1179_CR72","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra, S. V. et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377, 721\u2013731 (2011).","journal-title":"Lancet"},{"key":"1179_CR73","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1093\/rheumatology\/keae286","volume":"63","author":"EJ Arends","year":"2024","unstructured":"Arends, E. J. et al. Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus. Rheumatology 63, 2387\u20132398 (2024).","journal-title":"Rheumatology"},{"key":"1179_CR74","doi-asserted-by":"publisher","unstructured":"Struemper, H. et al. Reductions in circulating B cell subsets and immunoglobulin G levels with long-term belimumab treatment in patients with SLE. Lupus Sci. Med. https:\/\/doi.org\/10.1136\/lupus-2021-000499 (2022).","DOI":"10.1136\/lupus-2021-000499"},{"key":"1179_CR75","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13075-020-02177-0","volume":"22","author":"C Wilkinson","year":"2020","unstructured":"Wilkinson, C. et al. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis. Arthritis Res. Ther. 22, 102 (2020).","journal-title":"Arthritis Res. Ther."},{"key":"1179_CR76","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill, J. T. et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis Rheumatol. 70, 266\u2013276 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"1179_CR77","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu, D. et al. Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 83, 475\u2013487 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1179_CR78","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2024","unstructured":"Mathur, M. et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N. Engl. J. Med. 390, 20\u201331 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR79","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","volume":"96","author":"JR Myette","year":"2019","unstructured":"Myette, J. R. et al. A proliferation inducing ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 96, 104\u2013116 (2019).","journal-title":"Kidney Int."},{"key":"1179_CR80","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/art.40181","volume":"69","author":"HE Mei","year":"2017","unstructured":"Mei, H. E. et al. Plasmablasts with a mucosal phenotype contribute to plasmacytosis in systemic lupus erythematosus. Arthritis Rheumatol. 69, 2018\u20132028 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1179_CR81","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/art.37818","volume":"65","author":"N Sieger","year":"2013","unstructured":"Sieger, N. et al. CD22 ligation inhibits downstream B cell receptor signaling and Ca2+ flux upon activation. Arthritis Rheum. 65, 770\u2013779 (2013).","journal-title":"Arthritis Rheum."},{"key":"1179_CR82","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s12079-016-0322-1","volume":"10","author":"S Lumb","year":"2016","unstructured":"Lumb, S. et al. Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor. J. Cell Commun. Signal. 10, 143\u2013151 (2016).","journal-title":"J. Cell Commun. Signal."},{"key":"1179_CR83","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1901981","volume":"380","author":"X Montalban","year":"2019","unstructured":"Montalban, X. et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N. Engl. J. Med. 380, 2406\u20132417 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1179_CR84","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1136\/ard-2023-224691","volume":"83","author":"T Dorner","year":"2024","unstructured":"Dorner, T. et al. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sj\u00f6gren\u2019s syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial. Ann. Rheum. Dis. 83, 360\u2013371 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1179_CR85","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11095-019-2752-y","volume":"37","author":"P Chan","year":"2020","unstructured":"Chan, P. et al. Population pharmacokinetics, efficacy exposure-response analysis, and model-based meta-analysis of fenebrutinib in subjects with rheumatoid arthritis [corrected]. Pharm. Res. 37, 25 (2020).","journal-title":"Pharm. Res."},{"key":"1179_CR86","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1172\/JCI200319301","volume":"112","author":"AC Grammer","year":"2003","unstructured":"Grammer, A. C. et al. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. 112, 1506\u20131520 (2003).","journal-title":"J. Clin. Invest."},{"key":"1179_CR87","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/BOR.0000000000000825","volume":"33","author":"AL Stefanski","year":"2021","unstructured":"Stefanski, A. L. & Dorner, T. Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus. Curr. Opin. Rheumatol. 33, 592\u2013597 (2021).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1179_CR88","doi-asserted-by":"publisher","first-page":"iii64","DOI":"10.1136\/ard.2008.097972","volume":"67","author":"LH Calabrese","year":"2008","unstructured":"Calabrese, L. H. & Molloy, E. S. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann. Rheum. Dis. 67, iii64\u2013ii65 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1179_CR89","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann. Rheum. Dis. 83, 1304\u20131314 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"1179_CR90","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/s41591-024-02964-1","volume":"30","author":"L Bucci","year":"2024","unstructured":"Bucci, L. et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat. Med. 30, 1593\u20131601 (2024).","journal-title":"Nat. Med."},{"key":"1179_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114071","volume":"204","author":"M Subklewe","year":"2024","unstructured":"Subklewe, M. et al. Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study. Eur. J. Cancer 204, 114071 (2024).","journal-title":"Eur. J. Cancer"},{"key":"1179_CR92","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1136\/ard-2023-224152","volume":"82","author":"T Alexander","year":"2023","unstructured":"Alexander, T. et al. Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosus. Ann. Rheum. Dis. 82, 1497\u20131499 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1179_CR93","first-page":"359","volume":"35","author":"T Alexander","year":"2017","unstructured":"Alexander, T. & Hiepe, F. Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: time ready for a paradigm shift? Clin. Exp. Rheumatol. 35, 359\u2013361 (2017).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1179_CR94","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1093\/rheumatology\/keab877","volume":"61","author":"S Goklemez","year":"2022","unstructured":"Goklemez, S. et al. Long-term follow-up after lymphodepleting autologous haematopoietic cell transplantation for treatment-resistant systemic lupus erythematosus. Rheumatology 61, 3317\u20133328 (2022).","journal-title":"Rheumatology"},{"key":"1179_CR95","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3324\/haematol.2009.013458","volume":"95","author":"D Farge","year":"2010","unstructured":"Farge, D. et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years\u2019 experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 95, 284\u2013292 (2010).","journal-title":"Haematologica"},{"key":"1179_CR96","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000117824","volume":"119","author":"A Thiel","year":"2008","unstructured":"Thiel, A. et al. Direct assessment of thymic reactivation after autologous stem cell transplantation. Acta Haematol. 119, 22\u201327 (2008).","journal-title":"Acta Haematol."},{"key":"1179_CR97","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2017.0676","volume":"74","author":"D Baker","year":"2017","unstructured":"Baker, D., Herrod, S. S., Alvarez-Gonzalez, C., Giovannoni, G. & Schmierer, K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol. 74, 961\u2013969 (2017).","journal-title":"JAMA Neurol."},{"key":"1179_CR98","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/blood-2006-07-035766","volume":"109","author":"Y Loh","year":"2007","unstructured":"Loh, Y. et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood 109, 2643\u20132648 (2007).","journal-title":"Blood"},{"key":"1179_CR99","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie, R. A. et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann. Rheum. Dis. 81, 100\u2013107 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1179_CR100","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/ard.2007.079418","volume":"67","author":"G Cambridge","year":"2008","unstructured":"Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann. Rheum. Dis. 67, 1011\u20131016 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1179_CR101","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","volume":"78","author":"T Dorner","year":"2019","unstructured":"Dorner, T. et al. Treatment of primary Sj\u00f6gren\u2019s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann. Rheum. Dis. 78, 641\u2013647 (2019).","journal-title":"Ann. Rheum. Dis."},{"key":"1179_CR102","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","volume":"399","author":"SJ Bowman","year":"2022","unstructured":"Bowman, S. J. et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sj\u00f6gren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet 399, 161\u2013171 (2022).","journal-title":"Lancet"},{"key":"1179_CR103","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar3909","volume":"14","author":"HE Mei","year":"2012","unstructured":"Mei, H. E., Schmidt, S. & Dorner, T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res. Ther. 14, S1 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"1179_CR104","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","volume":"125","author":"HE Mei","year":"2015","unstructured":"Mei, H. E. et al. A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. Blood 125, 1739\u20131748 (2015).","journal-title":"Blood"},{"key":"1179_CR105","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1124\/jpet.123.001744","volume":"388","author":"A Deshmukh","year":"2024","unstructured":"Deshmukh, A. et al. Preclinical evidence for the glucocorticoid-sparing potential of a dual toll-like receptor 7\/8 inhibitor in autoimmune diseases. J. Pharmacol. Exp. Ther. 388, 751\u2013764 (2024).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1179_CR106","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/art.41953","volume":"73","author":"A Winkler","year":"2021","unstructured":"Winkler, A. et al. The interleukin-1 receptor-associated kinase 4 inhibitor PF-06650833 blocks inflammation in preclinical models of rheumatic disease and in humans enrolled in a randomized clinical trial. Arthritis Rheumatol. 73, 2206\u20132218 (2021).","journal-title":"Arthritis Rheumatol."},{"key":"1179_CR107","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41573-024-00959-8","volume":"23","author":"F Ramirez-Valle","year":"2024","unstructured":"Ramirez-Valle, F., Maranville, J. C., Roy, S. & Plenge, R. M. Sequential immunotherapy: towards cures for autoimmunity. Nat. Rev. Drug Discov. 23, 501\u2013524 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1179_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01237-9","volume":"15","author":"EL Hubbard","year":"2023","unstructured":"Hubbard, E. L. et al. Analysis of transcriptomic features reveals molecular endotypes of SLE with clinical implications. Genome Med. 15, 84 (2023).","journal-title":"Genome Med."},{"key":"1179_CR109","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.omtn.2022.11.016","volume":"30","author":"TA Le","year":"2022","unstructured":"Le, T. A. et al. Efficient CRISPR-Cas9-mediated mutagenesis in primary human B cells for identifying plasma cell regulators. Mol. Ther. Nucleic Acids 30, 621\u2013632 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1179_CR110","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748\u2013755 (2008).","journal-title":"Nat. Med."},{"key":"1179_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1043680","volume":"14","author":"T Muchamuel","year":"2023","unstructured":"Muchamuel, T. et al. Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responses. Front. Immunol. 14, 1043680 (2023).","journal-title":"Front. Immunol."},{"key":"1179_CR112","doi-asserted-by":"publisher","unstructured":"McDonnell, S. R. P. et al. Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus Sci. Med. https:\/\/doi.org\/10.1136\/lupus-2023-001112 (2024).","DOI":"10.1136\/lupus-2023-001112"},{"key":"1179_CR113","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-022-01278-3","volume":"8","author":"C Qin","year":"2023","unstructured":"Qin, C. et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal. Transduct. Target. Ther. 8, 5 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1179_CR114","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315990121","volume":"121","author":"C Qin","year":"2024","unstructured":"Qin, C. et al. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Proc. Natl Acad. Sci. USA 121, e2315990121 (2024).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1179_CR115","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/s41590-020-00814-z","volume":"21","author":"MC Woodruff","year":"2020","unstructured":"Woodruff, M. C. et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat. Immunol. 21, 1506\u20131516 (2020).","journal-title":"Nat. Immunol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01179-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01179-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01179-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T09:04:26Z","timestamp":1732179866000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-024-01179-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":115,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1038\/s41584-024-01179-5","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]},"assertion":[{"value":"2 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.D. declares honoraria for scientific advice from Abelzeta, BMS, Janssen, Novartis, Roche\/GNE and UCB, and fees for clinical studies (paid to the university) by BMS, Novartis, Eli Lilly & Company, Janssen and Roche. P.E.L. is co-founder of AMPEL Biosolutions and an adviser to Abelzeta.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}